Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtre
1.
Mem. Inst. Oswaldo Cruz ; 106(8): 986-992, Dec. 2011. graf
Article Dans Anglais | LILACS | ID: lil-610974

Résumé

In this study, we evaluated whether human serum and lipoproteins, especially high-density lipoprotein (HDL), affected serum amyloid A (SAA)-induced cytokine release. We verified the effects of SAA on THP-1 cells in serum-free medium compared to medium containing human serum or lipoprotein-deficient serum. SAA-induced tumour necrosis factor-alpha (TNF-α) production was higher in the medium containing lipoprotein-deficient serum than in the medium containing normal human serum. The addition of HDL inhibited the SAA-induced TNF-α release in a dose-dependent manner. This inhibitory effect was specific for HDL and was not affected by low-density lipoprotein or very low-density lipoprotein. In human peripheral blood mononuclear cells, the inhibitory effect of HDL on TNF-α production induced by SAA was less pronounced. However, this effect was significant when HDL was added to lipoprotein-deficient medium. In addition, a similar inhibitory effect was observed for interleukin-1 beta release. These findings confirm the important role of HDL and support our previous hypothesis that HDL inhibits the effects of SAA during SAA transport in the bloodstream. Moreover, the HDL-induced reduction in the proinflammatory activity of SAA emphasizes the involvement of SAA in diseases, such as atherosclerosis, that are characterized by low levels of HDL.


Sujets)
Humains , Interleukine-1 bêta/biosynthèse , Agranulocytes/métabolisme , Lipoprotéines HDL/pharmacologie , Protéine amyloïde A sérique/antagonistes et inhibiteurs , Facteur de nécrose tumorale alpha/biosynthèse , Milieux de culture sans sérum , Interleukine-1 bêta/effets des médicaments et des substances chimiques , Agranulocytes/effets des médicaments et des substances chimiques , Lipoprotéines LDL/pharmacologie , Lipoprotéines VLDL/pharmacologie , Monocytes/effets des médicaments et des substances chimiques , Monocytes/métabolisme , Protéine amyloïde A sérique/pharmacologie
2.
Experimental & Molecular Medicine ; : 325-333, 2009.
Article Dans Anglais | WPRIM | ID: wpr-136589

Résumé

Serum amyloid A (SAA) has been regarded as an important mediator of inflammatory responses. The effect of several formyl peptide receptor-like 1 (FPRL1) ligands on the production of IL-8 by SAA was investigated in human neutrophils. Among the ligands tested, LL-37 was found to specifically inhibit SAA-induced IL-8 production in transcriptional and post-transcriptional levels. Since SAA stimulated IL-8 production via ERK and p38 MAPK in human neutrophils, we tested the effect of LL-37 on SAA induction for these two MAPKs. LL-37 caused a dramatic inhibition of ERK and p38 MAPK activity, which is induced by SAA. LL-37 was also found to inhibit SAA-stimulated neutrophil chemotactic migration. Further, the LL-37-induced inhibitory effect was mediated by FPRL1. Our findings indicate that LL-37 is expected to be useful in the inhibition of SAA signaling and for the development of drugs against SAA-related inflammatory diseases.


Sujets)
Animaux , Humains , Rats , Peptides antimicrobiens cationiques/pharmacologie , Lignée cellulaire tumorale , Mouvement cellulaire , Chimiotaxie des leucocytes , Interleukine-8/biosynthèse , MAP Kinase Kinase Kinases/métabolisme , Granulocytes neutrophiles/effets des médicaments et des substances chimiques , Protéines proto-oncogènes/métabolisme , Récepteurs aux peptides formylés/métabolisme , Récepteurs de la lipoxine/métabolisme , Protéine amyloïde A sérique/antagonistes et inhibiteurs , Transduction du signal , Transcription génétique
3.
Experimental & Molecular Medicine ; : 325-333, 2009.
Article Dans Anglais | WPRIM | ID: wpr-136588

Résumé

Serum amyloid A (SAA) has been regarded as an important mediator of inflammatory responses. The effect of several formyl peptide receptor-like 1 (FPRL1) ligands on the production of IL-8 by SAA was investigated in human neutrophils. Among the ligands tested, LL-37 was found to specifically inhibit SAA-induced IL-8 production in transcriptional and post-transcriptional levels. Since SAA stimulated IL-8 production via ERK and p38 MAPK in human neutrophils, we tested the effect of LL-37 on SAA induction for these two MAPKs. LL-37 caused a dramatic inhibition of ERK and p38 MAPK activity, which is induced by SAA. LL-37 was also found to inhibit SAA-stimulated neutrophil chemotactic migration. Further, the LL-37-induced inhibitory effect was mediated by FPRL1. Our findings indicate that LL-37 is expected to be useful in the inhibition of SAA signaling and for the development of drugs against SAA-related inflammatory diseases.


Sujets)
Animaux , Humains , Rats , Peptides antimicrobiens cationiques/pharmacologie , Lignée cellulaire tumorale , Mouvement cellulaire , Chimiotaxie des leucocytes , Interleukine-8/biosynthèse , MAP Kinase Kinase Kinases/métabolisme , Granulocytes neutrophiles/effets des médicaments et des substances chimiques , Protéines proto-oncogènes/métabolisme , Récepteurs aux peptides formylés/métabolisme , Récepteurs de la lipoxine/métabolisme , Protéine amyloïde A sérique/antagonistes et inhibiteurs , Transduction du signal , Transcription génétique
SÉLECTION CITATIONS
Détails de la recherche